Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Activation of the impaired NAMPT/SIRT7/SOD2 axis restores alveolar progenitor cell renewal in idiopathic pulmonary fibrosis
Xuexi Zhang, Xue Liu, Yujie Qiao, Anas Rabata, Ningshan Liu, Changfu Yao, Tanyalak Parimon, Danica Chen, Cory Hogaboam, Peter Chen, Barry Stripp, Stephen J. Gardell, Dianhua Jiang, Paul W. Noble, Jiurong Liang
Xuexi Zhang, Xue Liu, Yujie Qiao, Anas Rabata, Ningshan Liu, Changfu Yao, Tanyalak Parimon, Danica Chen, Cory Hogaboam, Peter Chen, Barry Stripp, Stephen J. Gardell, Dianhua Jiang, Paul W. Noble, Jiurong Liang
View: Text | PDF
Research Article Cell biology Metabolism Pulmonology

Activation of the impaired NAMPT/SIRT7/SOD2 axis restores alveolar progenitor cell renewal in idiopathic pulmonary fibrosis

  • Text
  • PDF
Abstract

Alveolar type 2 (AT2) progenitor cell exhaustion and impaired regenerative capacity are key pathogenic hallmarks in idiopathic pulmonary fibrosis (IPF). Nicotinamide adenine dinucleotide (NAD+) functions as a central regulator of cellular energy metabolism. We have previously reported that downregulation of NAD+-dependent sirtuin signaling contributes to the impaired progenitor cell function of IPF AT2 cells. In this study, we found that a key NAD+ biosynthesis enzyme, nicotinamide phosphoribosyltransferase (NAMPT), was significantly downregulated in IPF AT2 cells. NAMPT deficiency impaired AT2 renewal and enhanced lung fibrosis through downregulation of SIRT7 and SOD2, which resulted in increased oxidative stress, mitochondrial dysfunction, accumulated aberrant transitional cells, and impaired differentiation from AT2 to alveolar type 1 (AT1) cells. A mouse model with AT2-specific deletion of Nampt showed severely impaired AT2 renewal capacity and increased susceptibility to bleomycin lung injury. Activation of NAMPT by small-molecule activators promoted IPF AT2 renewal and reversed lung fibrosis in WT mice. NAMPT activation is a potentially promising therapeutic strategy for restoring AT2 progenitor cell function and halting or reversing progressive pulmonary fibrosis.

Authors

Xuexi Zhang, Xue Liu, Yujie Qiao, Anas Rabata, Ningshan Liu, Changfu Yao, Tanyalak Parimon, Danica Chen, Cory Hogaboam, Peter Chen, Barry Stripp, Stephen J. Gardell, Dianhua Jiang, Paul W. Noble, Jiurong Liang

×

Figure 3

NAMPT is associated with SOD2 expression and the oxidative stress response in AT2 cells.

Options: View larger image (or click on image) Download as PowerPoint
NAMPT is associated with SOD2 expression and the oxidative stress respon...
(A) UMAP visualization of NAMPT expression in total, NAMPThi, and NAMPTlo human AT2 cells. (B) Cell frequencies of the NAMPThi versus NAMPTlo AT2 cells in healthy and IPF lungs. (C) Violin plots showing SOD2 expression levels in NAMPThi and NAMPTlo human AT2 cells. (D and E) Violin plots showing expression levels of representative top DEGs of NAMPThi versus NAMPTlo AT2 cells. (D) Expression of HIF1A, TXNRD1, SFTPC, and SLC34A2 in NAMPThi and NAMPTlo. (E) Expression of SOD2, HIF1A, TXNRD1, NQO1, and ROMO1 in healthy and IPF AT2 cells. (F and G) Flow cytometric analysis of mitochondrial superoxide levels in immortalized AT2 cells from healthy and IPF lungs. (F) Gating strategy and (G) percentages of mitochondrial superoxide high (MitoSOX+) cells (n = 3/group; ****P < 0.0001, by unpaired, 2-tailed Student’s t test). (H and I) Flow cytometric analysis of mitochondrial superoxide levels in NAMPTKO and control immortalized AT2 cells, with and without bleomycin (100 μg/mL) treatment. (H) Gating strategy and (I) percentages of mitochondrial superoxide high (MitoSOX+) cells (n = 3/group; ****P < 0.0001, by 2-way ANOVA). (J) Fold change in the expression of antioxidant genes in AT2 cells from patients with IPF treated with NAT (10 μM) or DMSO control, analyzed by bulk RNA-seq. (K and L) Flow cytometric analysis of mitochondrial superoxide levels in immortalized IPF AT2 cells treated with NAT (10 μM) or DMSO control. (K) Gating strategy and (L) percentages of mitochondrial superoxidehi (MitoSOX+) cells (n = 3/group; ****P < 0.0001, by unpaired, 2-tailed Student’s t test). Data are shown as the mean ± SEM. All experiments were repeated at least 3 times. SSC-A, side scatter area; PE, phycoerythrin.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts